

**Senate Community Affairs Committee**

**ANSWERS TO ESTIMATES QUESTIONS ON NOTICE**

**HEALTH PORTFOLIO**

**Budget Estimates 2014 - 2015, 2/3 June 2014**

**Ref No:** SQ14-000592

**OUTCOME:** 2 - Access to Pharmaceutical Services

**Topic:** Life Saving Drugs Programme

**Type of Question:** Written Question on Notice

**Senator:** McLucas, Jan

**Question:**

How many applications are currently under assessment or have been assessed for access under the LSDP since September 2013?

**Answer:**

None.

Before a drug can be considered for listing on the Life Saving Drugs Programme (LSDP), it must firstly be accepted as clinically effective, but rejected for Pharmaceutical Benefits Scheme (PBS) listing by the Pharmaceutical Benefits Advisory Committee (PBAC), because it fails to meet the required cost-effectiveness criteria. Whilst two drugs have been submitted to PBAC for consideration for either PBS or LSDP listing since September 2013, both were recommended by the Committee for listing on the PBS and so were not considered for listing on the LSDP.